moleculin biotech, INC. (NASDAQ:MBRX) Files An 8-K Other Events
Item 8.01.
On March 15, 2017 at 12:00 p.m. (Eastern Time), Moleculin
Biotech, Inc. (the Company) will be featured as a presenting
company at the 29th Annual Roth Conference. Representatives of
the Company will use the presentation set forth as Exhibit 99.1
herein in connection with the foregoing presentation and in
various meetings with investors from time to time.
|
Item 9.01
|
Financial Statements and Exhibits.
|
|
99.1
|
Moleculin Biotech, Inc. Investor Presentation
|
|
99.2
|
Press release dated March 10, 2017
|
About moleculin biotech, INC. (NASDAQ:MBRX)
Moleculin Biotech, Inc. is a preclinical and clinical-stage pharmaceutical company. The Company is focused on the development of anti-cancer drug candidates. Its lead drug candidate is liposomal Annamycin, which it refers to as Annamycin, an anthracycline intended for the treatment of relapsed or refractory acute myeloid leukemia (AML). Annamycin is a Phase II clinical-stage anthracycline and liposome formulated anthracycline that has been designed to eliminate cardiotoxicity and avoid the multidrug resistance mechanisms. It has over two other drug development projects in progress, one involving a portfolio of small molecules, which it refers to as the WP1066 Portfolio, focused on the modulation of key oncogenic transcription factors involved in the progression of cancer, and the WP1122 Portfolio, a suite of molecules targeting the metabolic processes involved in cancer in general, and glioblastoma. As of September 30, 2016, it had not generated any revenue from its operations. moleculin biotech, INC. (NASDAQ:MBRX) Recent Trading Information
moleculin biotech, INC. (NASDAQ:MBRX) closed its last trading session down -0.02 at 1.13 with 316,444 shares trading hands.